FFilingSight

Regeneron Pharmaceuticals (REGN) 10-K Red Flags

Risk signals extracted deterministically from Regeneron Pharmaceuticals’s SEC 10-K/10-Q XBRL filings — no LLM, every finding cites the underlying data.

Detected red flags (9)

  • Restatement of financial statements: The term "restatement of" "previously issued" appears in 3 recent filing(s) (vs 1 in the prior period). This risk language is ongoing.
  • Endogenous analysis: 1 risk signal(s) detected versus 0 positive signal(s). The balance of evidence suggests elevated filing-specific risk that warrants monitoring in subsequent filings.
  • 1 new XBRL disclosure(s) in latest filing — expanding reporting scope.
  • 20 disclosure(s) dropped from prior year — reduced reporting granularity.
  • Ongoing high-severity risk language: Restatement of financial statements.
  • Market cap $79.00B at $840.84 per share.
  • Trailing P/E 20.27, P/S 5.51, P/B 2.49.
  • Restatement of financial statements: The term "restatement of" "previously issued" appears in 3 recent filing(s) (vs 1 in the prior period). This risk language is ongoing.
  • Endogenous analysis: 1 risk signal(s) detected versus 0 positive signal(s). The balance of evidence suggests elevated filing-specific risk that warrants monitoring in subsequent filings.

Filings & ownership

  • Latest annual report (10-K) filed Feb 4, 2026.
  • Latest quarterly report (10-Q) filed Jul 30, 2026.
  • 14 recent 8-K material-event filings in the index.
  • Recent insider Form 4s: 0 buy vs 0 sell transactions.
  • ~10,000+ recent 13F-HR filings reference Regeneron Pharmaceuticals; broad institutional reporting.
  • Recent filers include BAKER BROS ADVISORS LLC, BAKER BROS ADVISORS LLC, CANYON CAPITAL ADVISORS LLC.
  • 20 recent 13G passive institutional ownership notices.

Full REGN analyst report

Valuation (DCF & Graham), technicals, macro exposure, risk scorecard and 13F/13D ownership.

View full report →

Not investment advice. FilingSight is an automated analytical research tool, not a registered investment advisor. Ratings and scores are quantitative analytical classifications, not buy or sell recommendations. Nothing here is personalized to your circumstances. Investing involves risk of loss — consult a licensed professional. See full disclosures.